Bruker announced the acquisition of AST Revolution, a company that launched its WAVE™ and Arc™ rapid antimicrobial susceptibility testing platforms in August 2025. The deal adds a technology that delivers actionable results in a fraction of the time required by conventional culture methods, positioning Bruker to capture a growing share of the point‑of‑care diagnostics market.
The transaction was announced on Nov. 24, 2025, and financial terms were not disclosed. Bruker’s strategy, dubbed Project Accelerate 2.0, has focused on high‑growth life‑science verticals such as spatial biology, molecular diagnostics, and lab automation. Adding AST Revolution’s rapid AST platform aligns directly with that agenda, giving Bruker a foothold in the critical infectious‑disease diagnostics space where speed and accuracy are increasingly demanded by clinicians and payers.
Bruker’s Q3 2025 earnings report showed revenue of $860.5 million, a 0.5 % decline year‑over‑year, and a non‑GAAP EPS of $0.45. The company cited a challenging market environment and a shift in organic revenue mix as headwinds. The acquisition is expected to offset these pressures by expanding Bruker’s product mix and opening new revenue streams that can be leveraged across its existing scientific instruments and laboratory automation platforms.
Management emphasized that the integration of AST Revolution will accelerate Bruker’s ability to offer end‑to‑end diagnostic solutions. CEO Frank H. Laukien noted that the addition “strengthens our portfolio in a market where rapid, accurate testing is becoming a competitive differentiator.” The move also supports Bruker’s goal of achieving higher operating leverage through cross‑selling opportunities between the new rapid‑AST technology and its established instrument lines.
While the financial terms remain undisclosed, analysts expect the acquisition to contribute to Bruker’s long‑term growth trajectory. The company’s guidance for FY2025 was lowered in light of market softness, but the addition of AST Revolution is viewed as a strategic investment that could help Bruker regain momentum in a segment that is projected to grow at double‑digit rates over the next five years.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.